226 related articles for article (PubMed ID: 18694831)
1. Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.
López-Rodríguez R; Novalbos J; Gallego-Sandín S; Román-Martínez M; Torrado J; Gisbert JP; Abad-Santos F
Pharmacol Res; 2008 Jul; 58(1):77-84. PubMed ID: 18694831
[TBL] [Abstract][Full Text] [Related]
2. Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.
Ochoa D; Prieto-Pérez R; Román M; Talegón M; Rivas A; Galicia I; Abad-Santos F; Cabaleiro T
Pharmacogenomics; 2015; 16(9):939-48. PubMed ID: 26122864
[TBL] [Abstract][Full Text] [Related]
3. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic studies of enantiomers of ibuprofen and its chiral metabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes.
Karaźniewicz-Łada M; Luczak M; Główka F
Xenobiotica; 2009 Jun; 39(6):476-85. PubMed ID: 19480553
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
Tornio A; Niemi M; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2007 May; 63(5):463-9. PubMed ID: 17333159
[TBL] [Abstract][Full Text] [Related]
6. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
Martínez C; García-Martín E; Blanco G; Gamito FJ; Ladero JM; Agúndez JA
Br J Clin Pharmacol; 2005 Jan; 59(1):62-9. PubMed ID: 15606441
[TBL] [Abstract][Full Text] [Related]
7. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.
Dorado P; Cavaco I; Cáceres MC; Piedade R; Ribeiro V; Llerena A
Eur J Clin Pharmacol; 2008 Oct; 64(10):967-70. PubMed ID: 18548238
[TBL] [Abstract][Full Text] [Related]
8. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
9. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA; García-Martín E; Martínez C
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):607-20. PubMed ID: 19422321
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
Kirchheiner J; Roots I; Goldammer M; Rosenkranz B; Brockmöller J
Clin Pharmacokinet; 2005; 44(12):1209-25. PubMed ID: 16372821
[TBL] [Abstract][Full Text] [Related]
11. AKR1D1*36 C>T (rs1872930) allelic variant is associated with variability of the CYP2C9 genotype predicted pharmacokinetics of ibuprofen enantiomers - a pilot study in healthy volunteers.
Kapedanovska Nestorovska A; Jakjovski K; Naumovska Z; Sterjev Z; Geskovska NM; Mladenovska K; Suturkova L; Dimovski A
Acta Pharm; 2019 Sep; 69(3):399-412. PubMed ID: 31259734
[TBL] [Abstract][Full Text] [Related]
12. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Biochem Biophys Res Commun; 2002 Nov; 299(1):25-8. PubMed ID: 12435384
[TBL] [Abstract][Full Text] [Related]
13. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.
Kirchheiner J; Meineke I; Freytag G; Meisel C; Roots I; Brockmöller J
Clin Pharmacol Ther; 2002 Jul; 72(1):62-75. PubMed ID: 12152005
[TBL] [Abstract][Full Text] [Related]
14. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?
Durrmeyer X; Hovhannisyan S; Médard Y; Jacqz-Aigrain E; Decobert F; Barre J; Alberti C; Aujard Y; Danan C; Baud O
PLoS One; 2010 Aug; 5(8):e12329. PubMed ID: 20808793
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.
Prieto-Pérez R; Ochoa D; Cabaleiro T; Román M; Sánchez-Rojas SD; Talegón M; Abad-Santos F
J Clin Pharmacol; 2013 Dec; 53(12):1261-7. PubMed ID: 23996211
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.
Peiró AM; Novalbos J; Zapater P; Moreu R; López-Rodríguez R; Rodríguez V; Abad-Santos F; Horga JF
Pharmacol Res; 2009 Jan; 59(1):62-8. PubMed ID: 18992346
[TBL] [Abstract][Full Text] [Related]
17. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.
Hamman MA; Thompson GA; Hall SD
Biochem Pharmacol; 1997 Jul; 54(1):33-41. PubMed ID: 9296349
[TBL] [Abstract][Full Text] [Related]
18. [Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].
Martínez C; Blanco G; García-Martín E; Agúndez JA
Farm Hosp; 2006; 30(4):240-8. PubMed ID: 17022718
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2009 Dec; 10():124. PubMed ID: 19954515
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.
Wang Z; Wang S; Huang M; Hu H; Yu L; Zeng S
Chirality; 2014 Mar; 26(3):166-73. PubMed ID: 24464553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
